Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide

[1]  L. Jia,et al.  Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20 , 2020, Cell Death & Disease.

[2]  Xiao-ying Zhao,et al.  Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner , 2019, Oncology letters.

[3]  R. Advani,et al.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial , 2019, The Lancet.

[4]  You Won Lee,et al.  Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. , 2018, Cancer research.

[5]  Henry W. Long,et al.  A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing , 2018, Science.

[6]  J. M. Bradshaw,et al.  Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma , 2018, Leukemia.

[7]  M. Seto,et al.  Frequent expression of CD30 in extranodal NK/T‐cell lymphoma: Potential therapeutic target for anti‐CD30 antibody‐based therapy , 2018, Hematological oncology.

[8]  B. Bernstein,et al.  Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. , 2018, Cancer cell.

[9]  R. Young,et al.  Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. , 2017, Cancer discovery.

[10]  Dachuan Huang,et al.  Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. , 2017, Blood.

[11]  Swe Swe Myint,et al.  VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. , 2017, Cancer discovery.

[12]  S. Horwitz,et al.  Targeting histone deacetylases in T-cell lymphoma , 2017, Leukemia & lymphoma.

[13]  W. Xu,et al.  Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China , 2017, Journal of Hematology & Oncology.

[14]  Shawn M. Gillespie,et al.  Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. , 2017, Cell stem cell.

[15]  J. Soria,et al.  JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. , 2017, Cancer discovery.

[16]  T. Graeber,et al.  Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. , 2017, Cancer discovery.

[17]  James S. Duncan,et al.  Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. , 2017, Cancer discovery.

[18]  M. Lange,et al.  Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT. , 2017, Cancer cell.

[19]  E. Seto,et al.  HDACs and HDAC Inhibitors in Cancer Development and Therapy. , 2016, Cold Spring Harbor perspectives in medicine.

[20]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[21]  L. Sokol,et al.  An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma , 2016, Expert opinion on investigational drugs.

[22]  G. Meister,et al.  miRNA expression profiling of Epstein–Barr virus‐associated NKTL cell lines by Illumina deep sequencing , 2016, FEBS open bio.

[23]  D. Heo,et al.  Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities , 2015, Leukemia & lymphoma.

[24]  J. Vose,et al.  Management of extranodal natural killer/t-cell lymphoma, nasal type. , 2015, Clinical lymphoma, myeloma & leukemia.

[25]  Seungbok Lee,et al.  Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type , 2015, Oncotarget.

[26]  W. Xue,et al.  Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma , 2014, Nature Genetics.

[27]  Christopher J. Ott,et al.  An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia , 2014, Nature Genetics.

[28]  S. Pileri,et al.  CD30 expression in peripheral T-cell lymphomas , 2013, Haematologica.

[29]  Y. Kwong,et al.  SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. , 2012, Blood.

[30]  A. Riggs,et al.  Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation , 2012, Proceedings of the National Academy of Sciences.

[31]  M. J. Newman,et al.  Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity , 2012, Cancer Chemotherapy and Pharmacology.

[32]  Y. Natkunam,et al.  Clinicopathologic and Molecular Features of 122 Brazilian Cases of Nodal and Extranodal NK/T-Cell Lymphoma, Nasal Type, With EBV Subtyping Analysis , 2011, The American journal of surgical pathology.

[33]  P. Gaulard,et al.  Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. , 2011, Blood.

[34]  J. Becker,et al.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[36]  J. O’Shea,et al.  Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. , 2010, Immunity.

[37]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[38]  A. Sharrocks.  Faculty Opinions recommendation of JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. , 2009 .

[39]  R. Liang.  Advances in the management and monitoring of extranodal NK/T‐cell lymphoma, nasal type , 2009, British journal of haematology.

[40]  Andrew J. Bannister,et al.  JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin , 2009, Nature.

[41]  H. Dyson,et al.  Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains , 2009, The EMBO journal.

[42]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[43]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  K. Ohshima,et al.  Extranodal NK/T‐cell lymphoma: diagnosis and treatment cues , 2008, Hematological oncology.

[45]  Richard Pazdur,et al.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. , 2007, The oncologist.

[46]  C. Allis,et al.  Chromatin remodeling and cancer, Part I: Covalent histone modifications. , 2007, Trends in molecular medicine.

[47]  M. Wasik,et al.  STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..